ZoBio strives to provide attractive, validated chemical starting points for your drug discovery projects. To achieve this goal, we have been building and maintaining the ZoBio fragment library since 2003. Our fragment library has been screened against more than 100 targets…
NMR in Target Driven Drug Discovery: Why Not?
NMR is a powerful and information rich tool that can provide critical information at many stages of the pre-clinical drug discovery process.
In a recent publication ZoBio scientists discuss a number of examples…
Mirati and ZoBio Collaborate to Advance Targeted Oncology Programs
Mirati Therapeutics has selected ZoBio to provide fragment-based screening, biophysical compound characterization and structural biology for several oncology targets. In this arrangement, ZoBio screens…
Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms
MILAN, IT, AND LEIDEN, NL
Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads.
This alliance provides access to a synergistic, industry-leading…